Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 20, 2016. The report serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.56 |
| Volume | 351 shares |
| Date of Transaction | July 18, 2016 |
| Place of Transaction | London Stock Exchange (XLON) |
Material Changes
The filing details an acquisition of 351 ordinary shares by Dr. S. Dexter, a PCA of Dr. P. J. T. Vallance (President, Pharmaceuticals R&D). This transaction resulted from the re-investment of dividends paid to shareholders on July 14, 2016. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a notification of a share purchase event.
Key Facts for Investor Verification
- The transaction was an automatic dividend re-investment, not a discretionary open-market purchase.
- The individual involved, Dr. S. Dexter, is a PCA of a senior executive (Dr. P. J. T. Vallance).
- The transaction volume (351 shares) is nominal relative to the company's total share capital.
- The filing does not contain any financial results or strategic updates for the period.